Drugs / RGN-137
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03578029 | May 2019 → Sep 2021 | epidermolysis bullosa dystrophica, junctional epidermolysis bullosa | Lenus Therapeutics, LLC | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-08-05 | RegeneRx Biopharmaceuticals, Inc. | Results First Patient Enrolled in RGN-137 Trial for Epidermolysis Bullosa Experiences Complete Wound Healing regenerx.com ↗
According to a statement released by Lenus Therapeutics, the first patient was enrolled, treated, and complete wound healing was achieved in the wound treated with RGN-137 but not in the wound treated with placebo. |
| 2018-10-29 | RegeneRx Biopharmaceuticals, Inc. | Regulatory RegeneRx Partner Updates on Clinical Trials regenerx.com ↗
In terms of the regulatory aspect, the FDA already approved our Open Study Protocol. |
| 2017-02-27 | RegeneRx Biopharmaceuticals, Inc. | Regulatory RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S. regenerx.com ↗
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT Co., Ltd., received a positive response from the U.S. FDA for its Phase 3 clinical trial design for RGN-137 to treat epidermolysis bullosa ("EB"). |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGN-137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03578029 ↗ |
| Route | Topical | “It will be applied topically to the appropriate wound once a day for up to 84 days.” NCT03578029 ↗ |